## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP
O 17 (1 E.III.E. 1 1 1	0. 0.0.0.0	O III DEIIEI IOI/IE	O 1111121101111

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date				2A. Deemed Execution Date,	Acquired, Disposed of, or Benefi  3.			5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect	
(City)	(State)	(Zip)					<u> </u>				
(Cit.)	(Ctata)	(7in)						Person			
SAN CLEMENTE CA 92673							X	Form filed by One Form filed by Mor			
(Sirect)			4. If	Amendment, Date	of Original File	ed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Last) 951 CALLE AM	(First) MANECER	(Middle)		ate of Earliest Trans 21/2018	saction (Montl	n/Day/Year)	X	below) "	below) and Gen'l Mgr.		
1. Name and Address of Reporting Person*  BURCAR ALISON D				suer Name <b>and</b> Tic U MEDICAL			(Check	tionship of Reportin all applicable) Director Officer (give title	Person(s) to Issuer  10% Owner  Other (specify		

#### (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) (A) or (D) Price Amount Code Common Stock 06/21/2018 13,219 \$88.76 13,219 D X Common Stock 06/21/2018 X 1,976 Α \$58.79 15,195 D 3,320 D \$295.27(1) D Common Stock 06/21/2018 s 11,875 Common Stock 06/21/2018 s 4,704 D \$296.34(2) 7,171 D 5,502 \$297.38(3) Common Stock 06/21/2018 S D 1,669 D s \$298.24(4) Common Stock 06/21/2018 1,412 D 257 D Common Stock 06/21/2018 s 257 D \$301.12(5) 0 D

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$58.79	06/21/2018		X			1,976	(6)	02/24/2024	Common Stock	1,976	\$0.0 <sup>(7)</sup>	0	D	
Non- Qualified Stock Option (right to buy)	\$88.76	06/21/2018		X			13,219	(8)	02/11/2025	Common Stock	13,219	\$0.0 <sup>(7)</sup>	0	D	

### Explanation of Responses:

- 1. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$294.75 to \$295.75, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 2. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$295.80 to \$296.80, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 3. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$296.85 to \$297.85, inclusive. The reporting person undertakes to provide ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
- within the range set forth in this Form 4.

  4. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$297.95 to \$298.50, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
- within the range set forth in this Form 4.

  5. The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$301.00 to \$302.00, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
- within the range set forth in this Form 4.

  6. Options exercisable in four equal annual cumulative installments commencing one year after the grant date.
- 7. Transaction is the exercise of a derivative security; see Column 2.

8. Options exercisable one-third annually over the first three anniversaries of the grant date.

#### Remarks:

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

By: Alejandro Parras, Attorney-In-Fact For: Alison Burcar

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.